A new study suggests that maybe we should be treating patients with prediabetes with not just one but three antidiabetes drugs.

In the STOP DIABETES trial,[1] 81 prediabetes patients determined to be at high risk for progression to diabetes were treated with low-dose metformin, pioglitazone, and a GLP-1 receptor agonist. A larger group of 141 patients determined to be at intermediate risk were treated with metformin and pioglitazone. Both groups also received lifestyle therapy, as did patients who refused pharmacotherapy.

свернуть